 NEW YORK, March 11, 2022 GLOBE NEWSWIRE -- Cellectis the Company Euronext Growth: ALCLS - NASDAQ: CLLS, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that management will participate in the Oppenheimer Co. Annual Healthcare Conference, taking place March 15-17, 2022 as well as the Barclays Global Healthcare Conference, taking place March 15-17. Details for both presentations are below: 